Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the approval of ramucirumab plus paclitaxel for gastric cancer.

Venook says the approval is a benefit for all oncologists. While ramucirumab was already being combined with other agents, oncologists now know its benefit when combined with paclitaxel.

Ramucirumab’s expanded approval was based on two studies- one evaluating the drug as monotherapy and one evaluating the drug in combination with a taxane, Venook says.

Venook also says that ramucirumab is being evaluated in other disease.

View more from the 2014 Chemotherapy Foundation Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

PER® Chemotherapy Foundation Symposium (CFS)

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the approval of ramucirumab plus paclitaxel for gastric cancer

Dr. Venook Discusses the Approval of Ramucirumab Plus Paclitaxel